Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Autolus Therapeutics Plc ADR (NQ: AUTL )

4.515 -0.285 (-5.94%)
Streaming Delayed Price Updated: 11:08 AM EDT, Oct 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Autolus Therapeutics Plc ADR

< Previous 1 2 3 Next >
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
AUTL Stock Earnings: Autolus Therapeutics Misses EPS for Q2 2024
AUTL stock results show that Autolus Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
A Glimpse Into The Expert Outlook On Autolus Therapeutics Through 5 Analysts
Via Benzinga
Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget
Since wealth without health is utterly meaningless, investors may have some confidence with these biotech stocks to buy. 
Via InvestorPlace
Crude Oil Gains 1%; GameStop Shares Plunge
Via Benzinga
Exposures Fossil Fuels
Why Cracker Barrel Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
AUTL Stock Earnings: Autolus Therapeutics Misses EPS, Misses Revenue for Q1 2024
AUTL stock results show that Autolus Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Despegar.com Posts Strong Sales, Joins Reddit, Robinhood And Other Big Stocks Moving Higher On Friday
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Breaking Down Autolus Therapeutics: 4 Analysts Share Their Views
Via Benzinga
Autolus Therapeutics's Earnings Outlook
Via Benzinga
Analyst Expectations for Autolus Therapeutics's Future
Via Benzinga
Where Autolus Therapeutics Stands With Analysts
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Earnings Scheduled For March 14, 2024
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter. 
Via Benzinga
Preview: Autolus Therapeutics's Earnings
Via Benzinga
The Latest Analyst Ratings for Autolus Therapeutics
Via Benzinga
Chart Of The Day: Autolus Therapeutics - Effective Cancer Treatments
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. 
Via Talk Markets
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Autolus Therapeutics' Obe-Cel's Shows Compelling Safety Over Gilead's Drug For Acute Lymphoblastic Leukemia
Truist has raised the price target for Autolus Therapeutics PLC (NASDAQ: AUTL) from $6 to $9  
Via Benzinga
Earnings Outlook For Autolus Therapeutics
Via Benzinga
3 Top Penny Stock Picks You Haven’t Heard Of
Here are three penny stock picks investors likely haven't heard of, but probably should keep on the radar as speculative options. 
Via InvestorPlace
Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Tesla To Rally More Than 12%? Here Are 10 Other Analyst Forecasts For Wednesday
HC Wainwright & Co. cut the price target for DURECT Corporation (NASDAQ: DRRX) from $35 to $32. HC Wainwright & Co. analyst Ed Arce maintained a Buy rating. DURECT shares fell 1.3% to close at $4.75 on... 
Via Benzinga
Dow Tumbles 100 Points; Silver Rises Over 2%
U.S. stocks traded mostly lower toward the end of trading with the Dow Jones dropping 100 points on Friday 
Via Benzinga
Why Ambrx Biopharma Shares Are Trading Higher By Over 550%? Here Are 52 Stocks Moving In Friday's Mid-Day Session
Gainers Ambrx Biopharma Inc. (NYSE: AMAM) shares jumped 551.4% to $2.67 after the company announced preliminary Phase 2 results from its ACE-Breast-03 study showing a 57.1% overall response rate. 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.